Company Description
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats.
In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs.
It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.
It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.
Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1999 |
| IPO Date | Feb 10, 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 539 |
| CEO | Michael Egholm |
Contact Details
Address: 2 Tower Place, Suite 2000 South San Francisco, California 94080 United States | |
| Phone | 650 266 6000 |
| Website | standardbio.com |
Stock Details
| Ticker Symbol | LAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001162194 |
| CUSIP Number | 34385P108 |
| ISIN Number | US34385P1084 |
| Employer ID | 77-0513190 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Egholm Ph.D. | President, Chief Executive Officer and Director |
| Hanjoon Kim | Interim Chief Financial Officer and Chief Operating Officer |
| David Holmes | Investor Relations |
| Sean Mackay | Chief Business Officer and Senior Vice President |
| Dr. Stephen A. Williams BS, MB, Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 21, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | 144 | Filing |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 30, 2024 | 8-K | Current Report |
| Aug 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 6, 2024 | 10-Q | Quarterly Report |